6 Melanoma Helper Peptide Vaccine

What is 6 Melanoma Helper Peptide Vaccine?

6 Melanoma Helper Peptide Vaccine (6MHP) is a multi-epitope vaccine of six class II MHC-restricted peptides derived from gp100, MelanA/MART-1, tyrosinase, MAGE-A3 and MAGE-A1,2,3,6. It is designed to induce an antigen-specific, Th1-dominant CD4+ T-cell response that may augment cytotoxic T-cell responses. It is studied in melanoma, including uveal melanoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

6MHP

Drug type

Vaccine (Peptide vaccine)

Targets

gp100 (PMEL) (antigen), MelanA/MART-1 (antigen), tyrosinase (antigen), MAGE-A3 (antigen), MAGE-A1,2,3,6 (antigen)

Mechanism

Immune activation, directed at gp100 (PMEL), MelanA/MART-1 and tyrosinase

Pathways

CD4+ Th1-dominant T-cell response, CD8+ CTL response via epitope spreading, immunologic memory

Therapy area

Oncology

In trials of

CLDX

FDA status

Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

MelanomaOcular MelanomaUveal Melanoma

Sources

• NCI Thesaurus
• ClinicalTrials.gov NCT04364230

Updated Oct 11, 2026.